Specialty drug and medical device maker Baxter International Inc. said it will spend up to $330 million to acquire ApaTech, a privately held British concern that makes bone and soft tissue replacement material using biochemistry.
Baxter said it will pay $240 million cash for the orthobiologic products company and then pay up to $90 million more when sales milestones are reached. The deal is expected to close in the first quarter.
The acquisition will give Baxter a bone graft material called Actifuse marketed in the United States and Europe. The Deerfield, Ill., company also will acquire U.S., British and German manufacturing and research sites.
Baxter called ApaTech's product pipeline "highly complementary to our existing commercial and technical capabilities in biosurgery."
Latest from Today's Medical Developments
- Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio
- Star Cutter introduces Double Pilot Reamer
- #80 Manufacturing Matters - Machining Strategies to Save Time and Improve your Process for MedTech Components with Kennametal Inc.
- Real-world parts and expert manufacturing advice
- Experts discuss the latest in toolholding technology
- How permanent magnets are powering medical innovation
- Forecasting the year ahead in design and manufacturing
- Tecomet, Orchid Orthopedic Solutions announce merger agreement
